FABP5

Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy

Retrieved on: 
Tuesday, April 23, 2024
Pain, FDA, Brain, Cancer, Food, Prognosis, Survival, Breast, Research, FABP5, Transport, Dicarboxylic acid, IND, Drug discovery, Patient, Metabolism, Neuropathic pain, FABP, FABP7, Chemotherapy-induced peripheral neuropathy, Pharmaceutical industry

Additionally, the evidence shows that both genetic and pharmacological inhibition of FABP7 led to reduced tumor cell growth, migration, and invasion in multiple studies.

Key Points: 
  • Additionally, the evidence shows that both genetic and pharmacological inhibition of FABP7 led to reduced tumor cell growth, migration, and invasion in multiple studies.
  • Moreover, inhibition of FABP7 improved host survival rates, particularly in brain cancers, indicating its role as a novel target in cancer.
  • In preclinical studies, ART26.12 demonstrated positive results in cancer, cancer bone pain, and painful neuropathies such as chemotherapy-induced peripheral neuropathy (CIPN).
  • For more information about Artelo Biosciences and our commitment to innovative therapies, please visit our website at www.artelobio.com

Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge

Retrieved on: 
Tuesday, March 12, 2024
Dermatology, Atopic dermatitis, Inflammation, JNJ, Research, American Academy, Cancer, FABP5, Skin, FABP, Pain, Epidermis, Oxidative stress, Pharmaceutical industry

SOLANA BEACH, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced its selection as a finalist in Johnson & Johnson’s (“J&J’s”; NYSE: JNJ) Innovation Challenge .

Key Points: 
  • SOLANA BEACH, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced its selection as a finalist in Johnson & Johnson’s (“J&J’s”; NYSE: JNJ) Innovation Challenge .
  • Artelo was awarded the opportunity to present preclinical dermatology research on ART26.12 in San Diego, California, on March 11, 2024, concurrent with the American Academy of Dermatology Annual Meeting.
  • "We are pleased to have been selected to present our ART26.12 program to the J&J immuno-dermatology leadership team," said Dr. Andrew Yates, Chief Scientific Officer of Artelo.
  • “Our drug discovery program is investigating several oral, small molecule, FABP5 inhibitors,” said Professor Saoirse O'Sullivan, Vice President Translational Science of Artelo.

Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12’s Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy

Retrieved on: 
Tuesday, January 23, 2024
Senior, Patient, Diabetic neuropathy, Oxaliplatin, Research, CIPN, Peripheral neuropathy, Chemotherapy-induced peripheral neuropathy, Discovery, Cancer, The Journal of Pain, IND, Food, Neuropathic pain, FDA, Pain, Doctor of Philosophy, FABP5, Fatty acid, Pharmaceutical industry

The research article, titled “ Discovery and preclinical evaluation of a novel inhibitor of FABP5, ART26.12, effective in Oxaliplatin-induced Peripheral Neuropathy ,” highlights Artelo’s pre-clinical asset, ART26.12, and its potential ability to treat and prevent Oxaliplatin-Induced Peripheral Neuropathy (OIPN) in a series of separate studies.

Key Points: 
  • The research article, titled “ Discovery and preclinical evaluation of a novel inhibitor of FABP5, ART26.12, effective in Oxaliplatin-induced Peripheral Neuropathy ,” highlights Artelo’s pre-clinical asset, ART26.12, and its potential ability to treat and prevent Oxaliplatin-Induced Peripheral Neuropathy (OIPN) in a series of separate studies.
  • ART26.12 is a Fatty Acid Binding Protein 5 (FABP5) inhibitor in development for the treatment of chemotherapy-induced peripheral neuropathy (CIPN), a type of neuropathic pain caused by chemotherapy as well as non-chemotherapy cancer treatments such as immunomodulating drugs.
  • Artelo has conducted multiple pre-clinical studies in painful neuropathies, including diabetic neuropathy, paclitaxel-induced peripheral neuropathy, and OIPN, the latter two of which has no FDA-approved treatment.
  • The Company previously reported a positive pre-IND (investigational new drug) meeting with the Food and Drug Administration (FDA) and anticipates filing the IND for ART26.12 in the first half of 2024.

Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12

Retrieved on: 
Monday, January 8, 2024
Food, IND, FDA, Pain, Cancer, Chemotherapy-induced peripheral neuropathy, CIPN, Worldwide, Diabetic neuropathy, Patient, Safety, FABP5, Therapy, Pharmaceutical industry

“We look forward to working with Worldwide once we obtain approval from the FDA to advance ART16.12 into Phase 1 clinical development,” commented Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences.

Key Points: 
  • “We look forward to working with Worldwide once we obtain approval from the FDA to advance ART16.12 into Phase 1 clinical development,” commented Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences.
  • “With Worldwide’s extensive experience in the neurology space and successful track record of assisting companies progress through trials, we believe we are well positioned to leverage ART26.12’s positive profile observed in multiple animal models of painful neuropathies to progress to human studies.”
    “We are excited to partner with the Artelo Biosciences team on their important advancement with ART26.12,” stated Peter Benton, President and Chief Executive Officer of Worldwide Clinical Trials.
  • Artelo has conducted five pre-clinical studies in painful neuropathies, including diabetic neuropathy and chemotherapy-induced peripheral neuropathy, the latter of which has no FDA-approved treatment.
  • The Company previously reported a positive pre-IND (investigational new drug) meeting with the Food and Drug Administration and anticipates filing the IND for ART26.12 in the first half of this year.

Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 13, 2023
Peripheral neuropathy, Absorption, Research, Food, Weight loss, Investment, FDA, Investigational New Drug, FABP5, Conference, Fatty acid, Solubility, Cancer, Drug development, Pain, Congress, Gordon Research Conferences, TMP, Cryptocurrency, Pharmaceutical industry, CBD

SOLANA BEACH, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today reported financial and operating results for the three months ended September 30, 2023 and provided a business update.

Key Points: 
  • “We are pleased to report continued progress toward achieving meaningful milestones,” commented Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences.
  • Notably, ART12.11 demonstrated improved pharmaceutical properties in preclinical chronic stress models due to its novel co-crystallization.
  • Financial Results Ended September 30, 2023
    Operating expenses for the three months ended September 30, 2023, were $2.6 million compared to $2.4 million for the same period in 2022.
  • As of September 30, 2023, the Company had approximately $12.9 million in cash and investments, compared to $17.5 million as of December 31, 2022.

Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023

Retrieved on: 
Thursday, November 2, 2023
Science, Washington Convention Center, FDA, IND, Schulich School of Medicine & Dentistry, Chemotherapy-induced peripheral neuropathy, Food, Neuropathic pain, Health, News, Walter E. Washington Convention Center, Research, Poster, Society, Walter, CIPN, University, Depression, Cancer, Anxiety, D.C, Pain, Diabetic neuropathy, Cannabidiol, FABP5, Investigational New Drug, Food and Drug Administration, Pharmaceutical industry, Neuroscience

Another poster will present work on Artelo’s proprietary cocrystal of cannabidiol and tetramethylpyrazine, ART12.11, which has demonstrated improved efficacy and bioavailability compared to cannabidiol alone in a model of anxiety and depression.

Key Points: 
  • Another poster will present work on Artelo’s proprietary cocrystal of cannabidiol and tetramethylpyrazine, ART12.11, which has demonstrated improved efficacy and bioavailability compared to cannabidiol alone in a model of anxiety and depression.
  • “We are very pleased to have two of our programs being featured at this year’s conference,” commented Dr. Andrew Yates, Chief Scientific Officer at Artelo Biosciences.
  • ART26.12 has demonstrated a positive effect in numerous animal models of painful neuropathies, including chemotherapy-induced peripheral neuropathy (CIPN) and diabetic neuropathy.
  • For more information about the conference, please visit Neuroscience 2023 .

Artelo Biosciences Completes Positive Pre-IND Meeting with FDA for ART26.12

Retrieved on: 
Thursday, September 7, 2023
Chemotherapy-induced peripheral neuropathy, FABP5, Diabetes, Cancer, Trial of the century, Pain, Investigational New Drug, Neuropathic pain, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Disease, Pharmaceutical industry

Based on the FDA’s feedback, the Company also announced that it plans to file an IND application for the use of ART26.12 in neuropathic pain in the first half of 2024.

Key Points: 
  • Based on the FDA’s feedback, the Company also announced that it plans to file an IND application for the use of ART26.12 in neuropathic pain in the first half of 2024.
  • The FDA reviewed the IND-enabling preclinical data, manufacturing plans, and clinical study protocol synopses, provided guidance, and answered Artelo's questions on the development plan.
  • “We greatly value the FDA's guidance as we complete our remaining IND-enabling studies," said Dr. Andrew Yates, Chief Scientific Officer at Artelo Biosciences.
  • "The guidance we received was positive and validating as we prepare to advance ART26.12 into the clinic.”
    Gregory Gorgas, CEO of Artelo Biosciences, further noted, “We look forward to filing an IND application in order to obtain clearance for the first-in-human ART26.12 Phase 1 clinical trial.

Artelo Biosciences Announces Important New Data on ART26.12 Demonstrating Positive Effects in Multiple Models of Neuropathic Pain at the 33rd Annual International Cannabinoid Research Society Symposium

Retrieved on: 
Tuesday, June 27, 2023
Diabetic neuropathy, Chemotherapy-induced peripheral neuropathy, FABP5, The Fear Is Excruciating, but Therein Lies the Answer, Diabetes, Allodynia, Cancer, National Center for Advancing Translational Sciences, Paclitaxel, ICRS, CIPN, Pain, Patient, International Cannabinoid Research Society, Neuropathic pain, FDA, Pharmaceutical industry

SOLANA BEACH, Calif., June 27, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, announced that Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo, presented preclinical data related to ART26.12, Artelo’s novel fatty acid binding protein 5 (FABP5) inhibitor at the 33rd International Cannabinoid Research Society (ICRS) Symposium in Toronto, Ontario, Canada.

Key Points: 
  • There are very limited therapeutic options currently available and these existing treatments are often associated with a significant and undesirable side effect profile.
  • According to Coherent Market Insights , the global neuropathic pain market is estimated to be valued at $7.6 billion.
  • “ART26.12 continues to demonstrate a positive effect in numerous animal models of painful neuropathies, specifically chemotherapy-induced peripheral neuropathy (CIPN) and diabetic neuropathy,” said Professor O’Sullivan.
  • Based on these results, we are highly encouraged by the potential of ART26.12 for the countless patients suffering from this often excruciating and debilitating condition.”

Artelo Biosciences Reports Fiscal 2022 Year-End Financial Results and Provides Business Update

Retrieved on: 
Friday, March 31, 2023
Cortex, Patent, Trinity College, University, FABP5, CB2, Neoplasm, Anxiety, Cerebral cortex, Oxaliplatin, Diabetic neuropathy, Weight loss, National Center for Advancing Translational Sciences, Cancer, Toxicity, Brain, Research, ICRS, Pain, Biochemistry, Trinity College Dublin, Cachexia, Patient, International Cannabinoid Research Society, School, FABP, Cannabidiol, Pharmaceutical industry, Cryptocurrency, CBD

SOLANA BEACH, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today reported financial and operating results for the fiscal year ended December 31, 2022 and provided a business update.

Key Points: 
  • SOLANA BEACH, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today reported financial and operating results for the fiscal year ended December 31, 2022 and provided a business update.
  • “We achieved meaningful clinical progress throughout 2022,” stated Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences.
  • Given ART27.13’s better-than-expected safety profile and absence of drug-related grade three or four toxicity, we elected to advance to a fourth cohort at a 650-microgram dose.
  • Fiscal 2022 Year-End Financial Results:
    Operating expenses for the year ended December 31, 2022 were $10.3 million compared to $4.0 million for the four months ended December 31, 2021, and $7.4 million for the year ended August 31, 2021.

Artelo Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 8, 2022
PTSD, FABP, Research, Neuroscience, Securities Exchange Act of 1934, Company, Security (finance), Drug Quality and Security Act, Industry, AstraZeneca, Pain, Weight gain, Organic acid, Anxiety, Securities Act of 1933, U.S. Securities and Exchange Commission, Weight loss, Inflammation, Cancer, Anorexia nervosa, Patient, Drug discovery, Investigational New Drug, Protein, Radiation, Doctor of Philosophy, Nasdaq, Peripheral neuropathy, CB2, CB1, Achievement, University, Toxicity, Dehydration, Society, FDA, GLOBE, Purging disorder, Investment, Nature, Appetite, Lipid, Private Securities Litigation Reform Act, Cannabinoid, Immune system, FABP5, International Cannabinoid Research Society, Human, Pharmaceutical industry, Renewable energy

SOLANA BEACH, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today reported financial and operating results for the three months ended September 30, 2022 and provided a business update.

Key Points: 
  • Once clinical results are evaluated, we expect to commence enrollment of our Phase 2a clinical trial near year-end, stated Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences.
  • With regulatory enabling research well underway, Artelo anticipates filing an Investigational New Drug application with the FDA late next year.
  • Financial Results Ended September 30, 2022
    Operating expenses for the three months ended September 30, 2022, were $2.4 million compared to $2.2 million for the same period in 2021.
  • Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions.